{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T03:46:12Z","timestamp":1789962372343,"version":"4.0.1"},"reference-count":27,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2024,1,21]],"date-time":"2024-01-21T00:00:00Z","timestamp":1705795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Clazosentan has been shown to prevent vasospasm and reduce mortality in patients after aneurysmal subarachnoid hemorrhage (SAH) and has been approved for clinical use in Japan; however, its systemic events in the elderly (aged \u2265 75 years) have not been well-documented. Here, we report serious\/intolerable cardiopulmonary complications requiring discontinuation of drug therapy in elderly SAH patients. In this single-center case series study, medical records of consecutive SAH patients treated postoperatively with clazosentan (10 mg\/h) between June 2022 and May 2023 were reviewed retrospectively. Thirty-three patients received clazosentan therapy, of whom six were elderly with a mean age of 80.3 \u00b1 5.2 (range 75\u201389) years. Among them, despite no obvious medical history of systemic abnormalities, clazosentan was discontinued in three (50%) patients due to pleural effusion and hypoxemia with or without hypotension at 5 \u00b1 3 days after therapy initiation, which was higher than the incidence for younger patients (15%). The elderly patients had significantly lower urine output (1935 \u00b1 265 vs. 1123 \u00b1 371 mL\/day, p = 0.03) and greater weight gain (2.1 \u00b1 1.1 vs. 4.2 \u00b1 1.9 kg from baseline, p = 0.04) than patients who completed the therapy. One 89-year-old female developed congestive heart failure and hydrostatic pulmonary edema associated with increased intravascular and lung volumes even after therapy was discontinued, while the remaining two cases recovered within 2 days after drug cessation. These results suggest that elderly patients are more vulnerable to fluid retention and have a higher risk of cardiopulmonary complications during clazosentan therapy than younger patients. Careful monitoring of urine volume and weight gain and caution regarding age- and therapy-related hemodynamic insufficiencies are required.<\/jats:p>","DOI":"10.3390\/medicina60010185","type":"journal-article","created":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T05:42:31Z","timestamp":1705902151000},"page":"185","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Cardiopulmonary Events of the Elderly (\u226575 Years) during Clazosentan Therapy after Subarachnoid Hemorrhage: A Retrospective Study from a Tertiary Stroke Center in Japan"],"prefix":"10.3390","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7770-379X","authenticated-orcid":false,"given":"Tatsushi","family":"Mutoh","sequence":"first","affiliation":[{"name":"Department of Surgical Neurology, Research Institute for Brain and Blood Vessels, Akita Cerebrospinal and Cardiovascular Center, Akita 010-0874, Japan"},{"name":"Department of Aging Research and Geriatric Medicine, Institute of Development, Aging and Cancer, Tohoku University, Sendai 980-8575, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Aono","sequence":"additional","affiliation":[{"name":"Department of Surgical Neurology, Research Institute for Brain and Blood Vessels, Akita Cerebrospinal and Cardiovascular Center, Akita 010-0874, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Seto","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, Akita Cerebrospinal and Cardiovascular Center, Akita 010-0874, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiro","family":"Kimoto","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, Akita Cerebrospinal and Cardiovascular Center, Akita 010-0874, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6720-9970","authenticated-orcid":false,"given":"Ryota","family":"Tochinai","sequence":"additional","affiliation":[{"name":"Department of Surgical Neurology, Research Institute for Brain and Blood Vessels, Akita Cerebrospinal and Cardiovascular Center, Akita 010-0874, Japan"},{"name":"Department of Aging Research and Geriatric Medicine, Institute of Development, Aging and Cancer, Tohoku University, Sendai 980-8575, Japan"},{"name":"Department of Veterinary Pathophysiology and Animal Health, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo 113-8654, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junta","family":"Moroi","sequence":"additional","affiliation":[{"name":"Department of Surgical Neurology, Research Institute for Brain and Blood Vessels, Akita Cerebrospinal and Cardiovascular Center, Akita 010-0874, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Surgical Neurology, Research Institute for Brain and Blood Vessels, Akita Cerebrospinal and Cardiovascular Center, Akita 010-0874, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1161\/CIR.0000000000000757","article-title":"Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association","volume":"141","author":"Virani","year":"2020","journal-title":"Circulation"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"983","DOI":"10.3171\/2020.1.JNS192848","article-title":"A register-based SAH study in Japan: High incidence rate and recent decline trend based on lifestyle","volume":"134","author":"Ikawa","year":"2020","journal-title":"J. Neurosurg."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Alsbrook, D.L., Di Napoli, M., Bhatia, K., Desai, M., Hinduja, A., Rubinos, C.A., Mansueto, G., Singh, P., Domeniconi, G.G., and Ikram, A. (2023). Pathophysiology of Early Brain Injury and Its Association with Delayed Cerebral Ischemia in Aneurysmal Subarachnoid Hemorrhage: A Review of Current Literature. J. Clin. Med., 12.","DOI":"10.3390\/jcm12031015"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S0140-6736(16)30668-7","article-title":"Spontaneous subarachnoid haemorrhage","volume":"389","author":"Macdonald","year":"2017","journal-title":"Lancet"},{"key":"ref_5","first-page":"e314","article-title":"2023 Guideline for the Management of Patients With Aneurysmal Subarachnoid Hemorrhage: A Guideline From the American Heart Association\/American Stroke Association","volume":"54","author":"Hoh","year":"2023","journal-title":"Stroke"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1186\/s13054-014-0482-4","article-title":"Impact of transpulmonary thermodilution-based cardiac contractility and extravascular lung water measurements on clinical outcome of patients with Takotsubo cardiomyopathy after subarachnoid hemorrhage: A retrospective observational study","volume":"18","author":"Mutoh","year":"2014","journal-title":"Crit. Care"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/MAJ.0000000000000561","article-title":"Transpulmonary thermodilution-based management of neurogenic pulmonary edema after subarachnoid hemorrhage","volume":"350","author":"Mutoh","year":"2015","journal-title":"Am. J. Med. Sci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s12028-023-01757-7","article-title":"Emergency Medical Management of Aneurysmal Subarachnoid Hemorrhage","volume":"39","author":"Vergouwen","year":"2023","journal-title":"Neurocrit. Care"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1385\/NCC:1:2:157","article-title":"Neurogenic pulmonary edema and other mechanisms of impaired oxygenation after aneurysmal subarachnoid hemorrhage","volume":"1","author":"Vespa","year":"2004","journal-title":"Neurocrit. Care"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Caylor, M.M., and Macdonald, R.L. (2023). Pharmacological Prevention of Delayed Cerebral Ischemia in Aneurysmal Subarachnoid Hemorrhage. Neurocrit. Care.","DOI":"10.1007\/s12028-023-01847-6"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Bruder, N., Higashida, R., Santin-Janin, H., Dubois, C., Aldrich, E.F., Marr, A., Roux, S., and Mayer, S.A. (2022). The REACT study: Design of a randomized phase 3 trial to assess the efficacy and safety of clazosentan for preventing deterioration due to delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. BMC Neurol., 22.","DOI":"10.1186\/s12883-022-03002-8"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s10143-023-02104-2","article-title":"Real-world data of clazosentan in combination therapy for aneurysmal subarachnoid hemorrhage: A multicenter retrospective cohort study","volume":"46","author":"Muraoka","year":"2023","journal-title":"Neurosurg. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Schupper, A.J., Eagles, M.E., Neifert, S.N., Mocco, J., and Macdonald, R.L. (2020). Lessons from the CONSCIOUS-1 Study. J. Clin. Med., 9.","DOI":"10.3390\/jcm9092970"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1161\/STROKEAHA.108.519942","article-title":"Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): Randomized, double-blind, placebo-controlled phase 2 dose-finding trial","volume":"39","author":"Macdonald","year":"2008","journal-title":"Stroke"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.3171\/2022.2.JNS212914","article-title":"Effects of clazosentan on cerebral vasospasm-related morbidity and all-cause mortality after aneurysmal subarachnoid hemorrhage: Two randomized phase 3 trials in Japanese patients","volume":"137","author":"Endo","year":"2022","journal-title":"J. Neurosurg."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"628956","DOI":"10.3389\/fphar.2020.628956","article-title":"Clinical pharmacology of clazosentan, a selective endothelin A receptor antagonist for the prevention and treatment of aSAH-related cerebral vasospasm","volume":"11","author":"Juif","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"100253","DOI":"10.1016\/j.wnsx.2023.100253","article-title":"Initial real-world experience of clazosentan for subarachnoid hemorrhage in Japan","volume":"21","author":"Maeda","year":"2024","journal-title":"World Neurosurg. X"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Ido, K., Kurogi, R., Kurogi, A., Nishimura, K., Arimura, K., Nishimura, A., Ren, N., Kada, A., Matsuo, R., and Onozuka, D. (2020). Effect of treatment modality and cerebral vasospasm agent on patient outcomes after aneurysmal subarachnoid hemorrhage in the elderly aged 75 years and older. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0230953"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1161\/STROKEAHA.114.004739","article-title":"Early intensive versus minimally invasive approach to postoperative hemodynamic management after subarachnoid hemorrhage","volume":"45","author":"Mutoh","year":"2014","journal-title":"Stroke"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Kuwano, A., Ishiguro, T., Nomura, S., Omura, Y., Hodotsuka, K., Tanaka, Y., Murakami, M., Kawamata, T., and Kawashima, A. (2023). Predictive factors for improvement of symptomatic cerebral vasospasm following subarachnoid hemorrhage by selective intra-arterial administration of fasudil hydrochloride. Interv. Neuroradiol., 15910199231155037.","DOI":"10.1177\/15910199231155037"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"L1118","DOI":"10.1152\/ajplung.00277.2006","article-title":"Extravascular lung water measurements and hemodynamic monitoring in the critically ill: Bedside alternatives to the pulmonary artery catheter","volume":"291","author":"Isakow","year":"2006","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s13054-017-1739-5","article-title":"Transpulmonary thermodilution: Advantages and limits","volume":"21","author":"Monnet","year":"2017","journal-title":"Crit. Care"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3218","DOI":"10.1161\/STROKEAHA.107.484634","article-title":"Goal-directed fluid management by bedside transpulmonary hemodynamic monitoring after subarachnoid hemorrhage","volume":"38","author":"Mutoh","year":"2007","journal-title":"Stroke"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1056\/NEJMoa1413687","article-title":"Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension","volume":"373","author":"Frost","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1164\/rccm.200307-957OC","article-title":"Sitaxsentan therapy for pulmonary arterial hypertension","volume":"169","author":"Barst","year":"2004","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension","volume":"346","author":"Rubin","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1124\/jpet.116.234930","article-title":"Endothelin ET(A) receptor blockade, by activating ET(B) receptors, increases vascular permeability and induces exaggerated fluid retention","volume":"361","author":"Vercauteren","year":"2017","journal-title":"J. Pharmacol. Exp. Ther."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/1\/185\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:46:35Z","timestamp":1760103995000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/1\/185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,21]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["medicina60010185"],"URL":"https:\/\/doi.org\/10.3390\/medicina60010185","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,21]]}}}